Abstract: A nitric oxide delivery device is provided that can be formed as a module that is insertable in a mating equipment bay in a gas delivery system found in one location, removed and used in conjunction with a transport gas delivery system when the patient is transported, and thereafter inserted in the equipment bay of a gas delivery system located at a second location. In a preferred embodiment, the device includes a housing having an NO supply port, an NO delivery port, a flow sensor port, and a conduit pneumatically connected to the NO supply port and the NO delivery port. A selector valve is positioned in the conduit and selectively moves between a first position wherein the NO supply port is pneumatically connected to the NO delivery port and a second position wherein the NO delivery port is pneumatically connected to a temporary supply of NO.

Abstract: A diving helmet bubble diverter comprises a front skirt portion and a rear skirt portion attached to the front skirt portion at one end. The rear skirt portion is configured for mounting onto the diving helmet breathing regulator assembly. The attached front and rear skirt portions form side pockets that divert exhaust air bubbles away from the diver's mask when the rear skirt portion is mounted onto the regulator assembly. The mounted rear skirt portion forms a protective barrier between the exterior wall of the diving helmet and the exhaust whisker of the breathing regulator assembly that prevents air bubbles exiting the whisker from coming into contact with the diving helmet during diving activities.

Abstract: The concentration of xenon, in a medical gas mixture of xenon as an active component with a known composition of oxygen and, optionally, nitrogen and/or helium recirculating through a medical device (103) in which carbon dioxide is introduced into the mixture, is monitored by removal (135, 133) of carbon dioxide downstream of the medical device (103) and subsequently passing the carbon dioxide-free gas through an ultrasonic gas analyser (143) upstream of the medical device. The gas analyzer determines the xenon concentration by measuring the time delay between transmission of an ultrahigh frequency ultrasonic pulse of at least 100 kHz axially through the sample chamber from a location at one end thereof and reflection of said pulse axially from the other end of the sample chamber back to said location. An analyser of novel construction is disclosed.

Abstract: A humidifier system for heating and humidifying respiratory gases has a housing with an inner chamber, a first port at the first end for connection to a ventilator breathing circuit and a second port at the second end for connection to a patient to supply respiratory gases to the patient and to receive exhaled gases from the patient. A body of heat moisture exchange (HME) material is located within the chamber, and a water permeable device is also located within the chamber. The housing has a water refill inlet communicating with the water permeable device. A water supply outside the housing is connected to the water refill inlet to supply water to the water permeable device. A heater mounted outside the housing supplies heat to the housing and maintains the housing at a selected temperature.

Abstract: A massage base having a top surface contains at least one massage node base wherein the massage node base is motile in relation to the massage base. At least one massage node is mounted on each of the massage node bases and at least partially protrudes from the top surface. The massage node is mounted for rote movement in relation to the massage base. A motor, connected to the massage node base, engages the massage node in rote movement in relation to the massage base.

Abstract: An interface mechanism is provided that removably unites a carbon dioxide absorption canister with a patient breathing circuit on a ventilator. The interface mechanism includes a cradle that is moveably positioned between a first position and a second position, wherein in the first position, the canister is coupled to the cradle and the cradle is positioned such that the canister is in fluid communication with the breathing circuit. In the second position, the canister is removable from the cradle and the cradle extends at an angle from the patient breathing circuit. The interface mechanism advantageously provides visual indication when the canister is removed and the breathing circuit is operating as a closed loop system, without CO2 filtration. The mechanism also facilitates efficient and accurate fluid connection between the carbon dioxide absorption canister and the breathing circuit.

Abstract: An edible product in accordance with the present invention involves an edible inner component made from a first material and an edible outer cover component substantially completely encapsulating the edible inner component. In one form of the invention, the inner component is in the form of a hairball treatment for cats and the outer component is a dough-like material. A system for producing the edible product includes a first material source for supplying a first edible material to form the inner component of the edible product, a second material source for supplying a second edible material to form the outer component of the edible product, and an extruder for continuously coextruding the first edible material and the edible second material to produce an elongated rope of edible product. A crimping apparatus receives the longitudinal rope extruded from the extruder for crimping the longitudinal rope to separate the longitudinal rope into individual edible products.

Abstract: Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation.

Abstract: Compounds of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating epithelium regrowth, inhibiting cutaneous fibroblast proliferation, decreasing collagen deposit, suppressing fibrogenic growth factor and subsiding inflammatory cytokine, and are useful inhibiting the main features of radiation cutaneous syndrome. Results include a decrease in skin swelling, promotion of epithelium healing, and prevention of cutaneous fibrosis, ulceration and necrosis. The present invention provides methods of treating, preventing or ameliorating radiation-induced skin damage by administering a therapeutically effective amount of a histone deacetylase inhibitor.

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.

Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.

Abstract: Lung surfactant compositions are provided which can form a swelling phase when dispersed in a medium containing electrolytes. Hereby, a more active spreading of the lung surfactant into the alveoli can be obtained after administration to the lungs. Further provided are a pharmaceutical composition and a pharmaceutical kit comprising a lung surfactant composition as well as to a method for the treatment, prevention and/or diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with a deficiency of a lung surfactant.

Abstract: A gel composition for use in etching the surfaces of teeth in preparation for prophylaxis, repair, or restoration, comprising an aqueous solution of an effective quantity of an acid; and a colloidal silica sol, wherein the silica portion of the sol comprises from about 3 to about 20 weight percent of the total etchant composition.

Abstract: This invention relates generally to compositions for whitening human teeth, and more particularly, to compositions that do not contain hydrocarbon humectants and which, when applied onto the surface of teeth, act to whiten without damage to tooth surfaces. It does contain a hydrogel, defined as a gel that does not contain a hydrocarbon humectant. A hydrocarbon humectant is defined as a carbon, hydrogen and oxygen compound which is used to prevent the oral care composition from hardening upon exposure to air or a carbon, hydrogen and oxygen compound which is used as a carrier for ingredients of an oral care composition.

Abstract: Acne is treated or prevented by the topical application of compositions containing an alkanolamine such as dimethylaminoethanol, tyrosine, and a sulfur ingredient such as lipoic acid or glutathione. Adjunct ingredients such as fatty acid esters of ascorbic acid, e.g., ascorbyl palmitate and &agr;-hydroxy acids may be included in the formulations. Compositions of the invention may be used alone, or, in many preferable embodiments, in combination with conventional acne medications such as anti-acne products containing salicylic acid, benzoyl peroxide, or a retinoid. In these embodiments, alkanolamine compositions of the invention are applied to affected skin areas first, and then a conventional acne medication is applied. This maximizes the efficacy of the treatment while minimizing skin irritation caused by conventional medications.

Abstract: Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

Abstract: The present invention relates to a liquid formulation for a feminine wipe. The preferred formulation has an anti-irritant agent, a pH adjuster namely citric acid, and at least one preservative.

Abstract: A powder comprising a core powder, a hydroxyapatite layered directly on the core, and zinc layered directly on the hydroxyapatite, suitable for use in cosmetics. The powder has a light reflection curve similar to that of the surface of the skin so that it exhibits good skin feeling and is superior in long wear effect for makeup and antibacterial effect. The powder is also superior in adsorbing, solidifying, or congealing the sebum components or body odor components, and is useful as an effective component for a sebum-adsorbent agent, a body deodorant or the like in addition to cosmetics.